These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
353 related articles for article (PubMed ID: 31801012)
21. New and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors. Gaspari AA; Tyring S Dermatol Ther; 2015; 28(4):179-93. PubMed ID: 26201310 [TBL] [Abstract][Full Text] [Related]
22. Drug safety evaluation of tildrakizumab for psoriasis: a review of the current knowledge. Ruggiero A; Camela E; Potestio L; Fabbrocini G; Megna M Expert Opin Drug Saf; 2022 Dec; 21(12):1445-1451. PubMed ID: 36527300 [TBL] [Abstract][Full Text] [Related]
23. Nonclinical safety of tildrakizumab, a humanized anti-IL-23p19 monoclonal antibody, in nonhuman primates. Santostefano M; Herzyk D; Montgomery D; Wolf J Regul Toxicol Pharmacol; 2019 Nov; 108():104476. PubMed ID: 31536773 [TBL] [Abstract][Full Text] [Related]
24. Tildrakizumab for the treatment of psoriasis. Sinclair R; Thirthar Palanivelu V Expert Rev Clin Immunol; 2019 Jan; 15(1):5-12. PubMed ID: 30394141 [No Abstract] [Full Text] [Related]
25. Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis. Leman J; Burden AD Br J Dermatol; 2012 Nov; 167 Suppl 3():12-20. PubMed ID: 23082811 [TBL] [Abstract][Full Text] [Related]
26. Brodalumab in the treatment of chronic plaque psoriasis. Gisondi P; Girolomoni G Expert Opin Biol Ther; 2020 Oct; 20(10):1175-1186. PubMed ID: 32463723 [TBL] [Abstract][Full Text] [Related]
27. Guselkumab in the treatment of moderate-to-severe plaque psoriasis. López-Sánchez C; Puig L Immunotherapy; 2020 Apr; 12(6):355-371. PubMed ID: 32314622 [TBL] [Abstract][Full Text] [Related]
28. Successful management of treatment resistant nail psoriasis with tildrakizumab. Simpson K; Low ZM; Howard A; Kern JS Australas J Dermatol; 2021 Aug; 62(3):390-393. PubMed ID: 34114645 [TBL] [Abstract][Full Text] [Related]
30. IL-23 inhibitors for moderate-to-severe psoriasis. Ibler E; Gordon KB Semin Cutan Med Surg; 2018 Sep; 37(3):158-162. PubMed ID: 30215632 [TBL] [Abstract][Full Text] [Related]
31. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. Armstrong AW; Read C JAMA; 2020 May; 323(19):1945-1960. PubMed ID: 32427307 [TBL] [Abstract][Full Text] [Related]
32. New and emerging therapies in psoriasis. Leonardi CL; Gordon KB Semin Cutan Med Surg; 2014 Mar; 33(2 Suppl 2):S37-41. PubMed ID: 24979544 [TBL] [Abstract][Full Text] [Related]
33. Anti-IL 23 biologics for the treatment of plaque psoriasis. Vu A; Ulschmid C; Gordon KB Expert Opin Biol Ther; 2022 Dec; 22(12):1489-1502. PubMed ID: 36243011 [TBL] [Abstract][Full Text] [Related]
34. Clinical improvement in psoriasis with specific targeting of interleukin-23. Kopp T; Riedl E; Bangert C; Bowman EP; Greisenegger E; Horowitz A; Kittler H; Blumenschein WM; McClanahan TK; Marbury T; Zachariae C; Xu D; Hou XS; Mehta A; Zandvliet AS; Montgomery D; van Aarle F; Khalilieh S Nature; 2015 May; 521(7551):222-6. PubMed ID: 25754330 [TBL] [Abstract][Full Text] [Related]
35. A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab. Ghazawi FM; Mahmood F; Kircik L; Poulin Y; Bourcier M; Vender R; Wiseman MC; Lynde C; Litvinov IV Front Med (Lausanne); 2021; 8():702776. PubMed ID: 34447766 [TBL] [Abstract][Full Text] [Related]
36. New biologics in psoriasis: an update on IL-23 and IL-17 inhibitors. Dong J; Goldenberg G Cutis; 2017 Feb; 99(2):123-127. PubMed ID: 28319618 [TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of emerging immunotherapies in psoriasis. Yiu ZZ; Warren RB Immunotherapy; 2015; 7(2):119-33. PubMed ID: 25713988 [TBL] [Abstract][Full Text] [Related]
38. Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations. Galluzzo M; Chiricozzi A; Cinotti E; Brunasso G; Congedo M; Esposito M; Franchi C; Malara G; Narcisi A; Piaserico S; Tiberio R; Argenziano G; Fabbrocini G; Parodi A Expert Opin Biol Ther; 2022 Mar; 22(3):367-376. PubMed ID: 34607513 [TBL] [Abstract][Full Text] [Related]